The active agent in Пиразидол may be part of symptomatic management across conditions presenting with episodic or fluctuating manifestations.

The medication is used in situations involving certain distressing symptoms, and is relevant for managing symptom clusters associated with Major Depressive Disorder (MDD), which includes persistent low mood, loss of interest (anhedonia), and feelings of helplessness. It is also applied when managing the overlapping psychological components of conditions like Fibromyalgia Syndrome.

“The primary goal is to support a sense of emotional balance and provide symptomatic relief that helps patients cope more steadily with difficult episodes.”

This therapeutic approach is relevant for easing co-morbid anxiety, nervousness, and fatigue. It is generally used in clinical settings that involve acute or unstable symptom patterns, when support for mood and functional activity is appropriate. It is often selected when the patient needs to manage symptoms of fatigue and supports general well-being during symptomatic phases.

Quick Fact: Relief for Co-Morbid Psychic Distress The medication is commonly used to help with the relief of associated anxiety symptoms that frequently accompany depressive states, contributing to easing the overall symptom load.

Regulatory References

1. National Center for Biotechnology Information (NCBI) website of the National Institutes of Health (NIH)

The eligibility for using Пиразидол (Pirlindole) is strictly defined by government regulatory documents, outlining specific groups who are prohibited from use and those for whom use requires caution or is not established.

Populations Who Must Not Use Пиразидол (Contraindicated)

The medicine is absolutely prohibited for use in patients with the following conditions or circumstances:

• Acute Hepatitis or Diseases of the Hematopoietic System (blood disorders).
• Hypersensitivity to Pirlindole or any components of the tablet.
• Concomitant MAO Inhibitors: Use with any other Monoamine Oxidase Inhibitor (MAOI) is strictly forbidden, as is commencing treatment within 14 days after discontinuing another MAOI.

Age- and Condition-Based Restrictions

These official statements define the regulatory scope of eligibility, distinguishing between absolute prohibitions and populations requiring conditional use or for whom data is insufficient.

Interactions with other medicines and products

Regulatory documentation for Pirlindole, which is classified as a Selective and Reversible Inhibitor of Monoamine Oxidase A (RIMA), defines several mandatory constraints regarding co-administration with other substances.

Formally Documented Interaction Constraints

Pharmacological Interaction Basis

These constraints are based on Pirlindole's mechanism leading to Additive Serotonergic Activity and the Potentiation of Pressor Effects of other agents. Furthermore, the official profile notes that interactions may be of greater clinical significance in patients with severe liver or kidney impairment where drug clearance may be compromised.

Пиразидол (Pirlindole) functions primarily as a reversible inhibitor of monoamine oxidase A (RIMA), targeting the MAO-A enzyme within the central nervous system. This interaction is non-covalent and short-acting, preventing the oxidative deamination of key monoamine neurotransmitters, specifically serotonin (5-HT) and norepinephrine (NE). Intracellularly, the inhibition of MAO-A reduces the catabolism of these neurotransmitters within presynaptic nerve terminals. This molecular blockade leads to an increased concentration of free 5-HT and NE available for vesicular packaging and subsequent release into the synaptic cleft. Additionally, Пиразидол is reported to have a secondary mechanism as a serotonin–norepinephrine reuptake inhibitor (SNRI), which further contributes to the net increase in the extracellular concentration of both monoamines. The sustained elevation of 5-HT and NE in the synapse results in greater postsynaptic receptor occupancy and signaling, modulating neurotransmission within various CNS circuits.

The administration of Пиразидол (Pirlindole) is governed by a protocol that dictates controlled oral administration, specific dose titration, and defined use patterns. The medication is available as 25 mg and 50 mg oral tablets, with the approved route of administration being strictly by mouth.

The standard adult regimen requires a low initial dose of 50 mg to 75 mg daily, usually split into two divided intakes. This starting dose must be gradually titrated in 25 mg to 50 mg increments under a healthcare professional's supervision. The recommended maintenance dose typically ranges from 150 mg to 300 mg per day, with the maximum allowed dose not to exceed 400 mg daily.

The medication schedule mandates that the total daily dose be taken in two or three separate administrations and, importantly, must be consumed during or immediately after a meal. Treatment at the established maintenance dose typically continues for two to four weeks. Subsequently, the dose must be gradually decreased according to a tapering protocol. A crucial administrative constraint requires a 14-day washout period when switching from certain other monoamine oxidase inhibitors to ensure proper use.

Research Evidence / Overview of Studies for Пиразидол

The research base for Pirlindole consists primarily of clinical studies that explore how symptoms change over defined time intervals. This overview summarizes the structure of the available evidence, focusing on the types of research conducted, the populations included, and areas where data are still limited or uncertain. Findings described below reflect group patterns observed in the studies, and research does not determine whether an individual will respond similarly.

Evidence for Use in Depressive Symptoms and Co-Morbid Anxiety

Research on Pirlindole was evaluated in studies exploring its use in adults diagnosed with Major Depressive Disorder (MDD), a condition characterized by fluctuating or episodic manifestations of low mood. The core evidence stems from short-term Randomized Controlled Trials (RCTs) that have been analyzed within Systematic Reviews and Meta-analyses. Studies monitored how symptoms evolved by documenting changes in overall depressive symptom severity and co-existing anxiety symptom severity using standardized measures (HDRS and HARS). Reports from systematic analyses described patterns observed where reported measurements of change were documented against those reported for other active antidepressant controls.

Evidence for Use in Fibromyalgia Syndrome (FMS)

Research examined the role of Pirlindole in adults with Fibromyalgia Syndrome (FMS), a condition marked by functional limitations. The research foundation is composed of a very limited number of Randomized Controlled Trials (RCTs). These studies explored outcomes related to physical discomfort, examining endpoints such as changes in the intensity of widespread pain (VAS) and documented changes in the count of tender points. Systematic reviews noted that the evidence is limited, and the overall certainty remains low due to the small number of trials and participant numbers. Reported measurements of change in pain and tender points were observed in some studies, but findings were mixed.

Long-Term Studies and Follow-Up Data

Research has explored outcomes over defined time intervals. The follow-up durations used in the core clinical studies for Pirlindole were largely short-term, typically ranging from 3 to 6 weeks, with some observation periods extending to an intermediate-term of around six months. Comparative evidence is lacking for extended periods, and research focusing on the understanding of long-term outcomes remains an area where data are still emerging.

Limitations and Research Gaps

Studies help show what has been observed so far, but the evidence base has several documented limitations. The certainty remains low for certain applications, and evidence quality varies across studies. Key issues include the modest sample sizes found in some clinical trials and questions about overall quality. Limited information for long-term outcomes is documented as a research limitation. Furthermore, data for certain groups remain insufficient, and results apply mainly to the populations studied.

Key Studies & References NCBI Bookshelf: Antidepressant Drug Management for MDD and Episodic Manifestations (Used for core indication compatibility and general pharmacological context)

Common questions about Пиразидол (FAQ)

Q: Does Pirazidol have a 'cumulative' effect, and how quickly does it start working?

Official documents for Pirazidol, similar to other medications in its class, do not specify an exact time for the start of the therapeutic effect. While the active substance begins its biochemical action immediately, noticeable changes in symptoms are typically observed over a period of several weeks following the start of treatment or a dose adjustment. The period of the prescribed treatment course is designed to allow time for the medication's impact on symptoms to be evaluated.

Q: After how many weeks can one expect any effect from Pirazidol?

Clinical studies and prescribing information indicate that a therapeutic maintenance dose is typically established and continued for two to four weeks. This period typically allows for the establishment of a maintenance dose, after which a healthcare professional can better assess any observable effects of the medication. Individual responses, however, may vary outside of these general observations.

Q: Can Pirazidol be taken with other cold or pain medications?

Regulatory information warns that combining Pirazidol with sympathomimetic agents may potentially enhance pressor effects, which can increase the risk of a hypertensive reaction. Since certain common cold and pain medications may contain these agents (such as decongestants), combining them requires specific evaluation to avoid potential interactions. The consideration of all co-administered drugs is a key point for discussion with a healthcare professional.

Q: Are there official warnings about combining Pirazidol and alcohol?

Official documents note that alcohol and other central nervous system depressants may enhance the sedative effects of Pirazidol. This combination can increase feelings of drowsiness or lethargy. Discussion of alcohol consumption with a prescribing specialist is a stated component of careful use.

Q: What studies were conducted comparing the effectiveness of Pirazidol with placebo?

The primary evidence base includes short-term Randomized Controlled Trials (RCTs) that explored depressive symptoms. These studies compared Pirazidol against other active antidepressant controls. While specific comparisons against an inactive placebo are implied by the nature of RCTs, the official summaries of evidence focus on observed changes versus active controls.

Q: Can coffee (caffeine) be drunk while taking Pirazidol?

Official sources do not contain direct warnings about caffeine consumption. However, regulatory information advises caution regarding combinations with sympathomimetic agents, which can potentiate pressor effects. The consumption of products that may affect blood pressure or heart rate is a factor to consider in discussions with a healthcare professional.

Q: Are there restrictions on physical activity while taking Pirazidol?

The official safety profile does not include explicit restrictions on physical exercise. However, caution is advised for patients with existing cardiovascular disorders, as the medication can influence blood pressure and heart rate. Concerns about physical activity, particularly in the context of cardiovascular health, are appropriate topics for discussion with a medical professional.

Q: What is the difference between Pirazidol and other SSRIs?

Pirazidol is classified as a Selective and Reversible Inhibitor of Monoamine Oxidase A (RIMA). This mechanism distinguishes it from Selective Serotonin Reuptake Inhibitors (SSRIs), which operate differently. Official regulatory documents strictly prohibit the combined use of Pirazidol and SSRIs due to the high risk of a serious adverse event known as Serotonin Syndrome.

Q: What should be done if it seems Pirazidol is not helping?

Regulatory information indicates that treatment requires time to assess the full therapeutic effect. If the expected response is not observed after the prescribed period, the regulation of therapy is determined by the treating physician. Decisions regarding dosage, treatment duration, or switching medications are the responsibility of the treating healthcare professional.

Q: Why does Pirazidol cause dry mouth?

Dry mouth is officially listed as a frequently reported side effect of Pirazidol. While the specific molecular reasons are not typically detailed in patient information, this effect may be related to the medication's influence on the central and autonomic nervous systems.

Q: Can Pirazidol cause insomnia or, conversely, severe drowsiness?

Yes, official clinical data indicates that both types of sleep disturbances are commonly reported side effects. These nervous system effects include insomnia (difficulty sleeping) and somnolence (drowsiness/sleepiness). Most common adverse events often diminish as the body adjusts to the medication.

Q: What unusual side effects can occur when taking Pirazidol?

The official documentation highlights several rare but serious potential reactions. These include the risk of Serotonin Syndrome, a potentially life-threatening condition, and the activation of mania or hypomania in susceptible individuals. These are generally considered clinically significant adverse reactions requiring immediate medical attention.

Q: How do I know if a side effect from Pirazidol is 'normal' and not dangerous?

Official documents distinguish between common, usually mild effects (such as headache or nausea) and potentially serious conditions like Serotonin Syndrome. Unexpected, worsening, or severe reactions, as opposed to common, mild effects, are typically reasons to contact a healthcare professional. Any reaction that is unusual or concerning should be reported to the prescribing physician.

Q: Why is Pirazidol sometimes prescribed 'at night'?

Official data lists drowsiness (somnolence) as a frequently reported side effect. If this effect occurs, physicians may recommend taking a portion or the entire daily dose in the evening. This is typically done to potentially mitigate the impact of drowsiness on daytime activities, although the administration schedule is always determined by the prescribing doctor.

Q: Is Pirazidol considered a 'new' or 'old' drug?

Pirazidol (Pirlindole) is an established therapeutic option that has been used for many years in various countries, particularly across Europe and Asia. Its classification as a reversible inhibitor of MAO-A (RIMA) distinguishes it from older, irreversible MAO inhibitors.

Q: What do studies say about the long-term consequences of taking Pirazidol?

Clinical studies that form the core evidence for Pirazidol primarily focus on short-term effects, typically ranging from three to six weeks, with some observations extending to about six months. Official sources indicate that data are limited and still emerging for extended periods, and comparative evidence regarding long-term outcomes is currently lacking.

Q: What is the official status of Pirazidol regarding driving a car or operating machinery?

Due to frequently reported side effects like dizziness and drowsiness, patients are generally advised to exercise caution when operating vehicles or complex machinery. Regulatory safety warnings indicate that assessment of individual tolerance is key before engaging in activities like driving or operating machinery.

Q: Is there a difference in effect if Pirazidol is taken before or after a meal?

The official administration protocol strictly requires that the medication be consumed during or immediately after a meal. This constraint is mandatory for the approved use of the medication, and the official patient information does not detail the consequences or difference in effect if this rule is not followed.

Q: Is Pirazidol a prescription drug or can it be bought without a prescription?

Pirazidol (Pirlindole) is classified as a synthetic prescription drug. Its acquisition requires a valid prescription from a qualified healthcare professional.

Q: What is the feature of Pirazidol compared to tricyclic antidepressants?

Pirazidol is classified as a RIMA (Reversible Inhibitor of MAO-A), while tricyclic antidepressants (TCAs) have a different pharmacological mechanism, primarily through reuptake inhibition. The official safety profile for Pirazidol is generally considered more favorable compared to older, non-selective MAO inhibitors.

Q: Is Pirazidol a sedative?

Pirazidol is classified as an antidepressant. While it is not formally classified as a sedative medication, official data does list drowsiness (somnolence) as a frequently reported side effect, which may result in a subjective sedative feeling for some patients.

Q: What is the information on the use of Pirazidol during breastfeeding?

Official regulatory documents indicate that the use of Pirazidol during lactation (breastfeeding) is not recommended. This advisory is issued due to the lack of sufficient clinical safety data to establish its safety profile for use by nursing mothers.

Q: What rare but serious side effects are mentioned in official documentation?

Official documentation highlights the risk of Serotonin Syndrome and the potential for the activation of mania or hypomania in certain individuals. Furthermore, caution is advised for patients with cardiovascular disorders due to the drug’s potential influence on blood pressure.

Q: Is it necessary to take any tests before starting Pirazidol?

While the prescribing information does not list mandatory pre-treatment laboratory tests for all patients, contraindications and warnings regarding conditions like acute hepatitis or impaired liver/kidney function are mentioned. These precautions imply that a physician must assess a patient’s baseline health status, which may involve relevant laboratory testing.

Q: Is the use of Pirazidol associated with a risk of increased blood pressure?

Official documentation notes that the drug can influence blood pressure and heart rate. There is a specific warning regarding its combination with sympathomimetic (pressor) agents, which carries the risk of a hypertensive reaction (increased blood pressure). This requires careful monitoring.

Q: Why should one carefully read the instructions before taking Pirazidol?

The patient instruction leaflet is a regulatory document containing all official information necessary for safe use. This includes the required conditions for use, specific contraindications, warnings about potential side effects, and information on drug interactions as defined by the official prescribing information.

How to Store and Dispose of Пиразидол (Pirlindole)

Official regulatory guidelines define specific requirements for the storage and disposal of this medicine, ensuring product stability and environmental safety.

Mandatory Storage Requirements

Disposal Protocol

The most recommended method for disposal is to return unused or expired Пиразидол to an authorized drug take-back program or pharmacy collection point. Do not dispose of the medicine by flushing it down a toilet or pouring it down a drain. If a take-back program is unavailable, mix the medicine with an unappealing material, place it in a sealed bag or container, and discard it in the household trash.